Treatment of osteoperesis: Current status and recent advances

Comprehensive Therapy

Volumn 28, Issue 2, 2002, Pages 109-122

  Theodorou, Daphne J ^a   Theodorou, Stavroula J ^a   Sartoris, David J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIADIAZINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DIURETIC AGENT; FLUORIDE; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THIAZIDE DIURETIC AGENT; VITAMIN D; ALENDRONIC ACID; ESTROGEN; PAMIDRONIC ACID; RALOXIFENE;

ESTROGEN THERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BONE MASS; CALCIUM INTAKE; CHILD; DIETARY INTAKE; DRUG APPROVAL; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; SECONDARY HYPERPARATHYROIDISM; TREATMENT CONTRAINDICATION;

BENZOTHIADIAZINES; CALCITONIN; CALCIUM; DIPHOSPHONATES; DIURETICS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FLUORIDES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; VITAMIN D;

EID: 0036017541     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-002-0048-2     Document Type: Article

References (167)

1. Calcium in the prevention and treatment of osteoporosis
2. Bone mass, nutrition and, other lifestyle factors
3. A review of calcium preparations
4. Calcium and peak bone mass
5. Calcium nutrition and bone health in the elderly
6. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
7. Prevention of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation and hormone-replacement therapy
8. Does calcium supplementation prevent postmenopausal bone loss? A double-blind controlled study
9. Osteoporosis: The structural and reparative consequences for the skeleton
10. Orthopaedic consequences of osteoporosis
11. Skeletal failure in osteoporosis
12. NIH Conference: Optimal calcium intake. NIH consensus development panel on optimal calcium intake
13. Nutrition and metabolic bone disease
14. Dietary calcium intake and rates of bone loss in women
15. Vitamin D3 and calcium to prevent hip fractures in the elderly women
16. Calcium bioavailability from calcium carbonate and calcium citrate
17. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: Relationship between serum 1,25-dihydroxy vitamin D and intestinal vitamin D receptor concentrations in normal women
18. An investigation of sources of variation in calcium absorption efficacy
19. Osteomalacia and osteoporosis
20. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: Implications for prevention of osteoporosis
21. Calcium bioavailability from two calcium carbonate preparations
22. A randomized placebo-controlled trial of calcium carbonate vs dairy supplementation in elderly N England women
23. Lactose intolerance and bone mass in postmenopausal Italian women
24. Bone mineral density in coeliac disease
25. Safety of some calcium supplements questioned
26. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: A randomized trial
27. Alfacalcidol (alpha D3) and calcium in osteoporosis
28. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3
29. Treatment of postmenopausal osteoporosis with calcitriol or calcium
30. Calcium homeostasis of an elderly population upon admission to a nursing home
31. Low serum 25-hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians
32. Effects of skin thickness, age, body fat, and sunlight on serum 25 hydroxy vitamin D
33. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1OHD3) and 2,24 dihydroxycholecalciferol (1,24 (OH)2D3)
34. Benefits and risks of estrogen replacement therapy
35. 17 Beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens
36. Increased osteoclast development after estrogen loss: Mediation by interleukin 6
37. Avian osteoclasts as estrogen target cells
38. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release
39. A practical guide to prescribing estrogen replacement therapy
40. Long-term estrogen replacement therapy prevents bone loss and fractures
41. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study
42. Prevention of spinal osteoporosis in oophorectomised women
43. Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution
44. Hip bone loss increases with advancing age: Longitudinal results from The Study of Osteoporotic Fractures
45. Estrogen and calcium supplement use among Japanese-American women: Effects upon bone loss when used singly and in combination
46. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy
47. Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist, and total body in late postmenopausal women
48. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis
49. The future of hip fractures in the United States: Numbers, costs, and potential effects of postmenopausal oestrogen
50. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy
51. The effect of postmenopausal estrogen therapy on bone density in elderly women
52. Bone response to termination of oestrogen treatment
53. Vertebral postmenopausal bone loss is reduced in overweight women: A longitudinal study in 155 early postmenopausal women
54. Cigarette smoking and bone mineral density in older men and women
55. Estrogen and estrogen-progestogen replacement: Therapy and cardiovascular diseases
56. Hormone replacement therapy for prevention and treatment of osteoporosis
57. Guidelines for osteoporosis prophylaxis
58. Estrogen replacement therapy in practice: Trends and issues
59. Overview of the clinical usefulness of bone mineral measurements in the prevention of postmenopausal osteoporosis
60. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
61. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
62. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
63. Estrogen replacement therapy: Indications and complications
64. Hormone therapy to prevent disease and prolong life in postmenopausal women
65. Hormonal treatment of postmenopausal women
66. Postmenopausal hormone therapy and mentality
67. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis
68. Decreased mortality in users of estrogen replacement therapy
69. Current concepts in estrogen replacement therapy in the menopause
70. Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery
71. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy
72. Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow-up from the Nurses' Health Study
73. Decrease of bone mineral density during estrogen substitution therapy
74. Exercise and other factors in the prevention of hip fracture: The Leisure World Study
75. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
76. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
77. The waning effect of postmenopausal estrogen therapy on osteoporosis
78. The prevention and treatment of osteoporosis
79. Treatment of postmenopausal osteoporosis with transdermal estrogen
80. Effect of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy premenopausal and postmenopausal women
81. Tamoxifen-panacea or Pandora's box?
82. Metabolic bone disease
83. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year open therapy
84. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate
85. The emerging role of biphosphonates in the prevention of bone metastases
86. Biphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease
87. Changes in bone histomorphometry after long-term treatment with intermittent cyclic etidronate for postmenopausal osteoporosis
88. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease
89. Diphosphonates and inhibition of bone mineralization
90. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate)
91. Biphosphonates: Mechanisms of action and clinical applications
92. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
93. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
94. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
95. Bone turnover in the cortical bone of primates. Effects of the amino-biphosphonate alendronate
96. Protocols of treatment of chronic back pain in involutional osteoporosis
97. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
98. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
99. Osteoporosis: Diagnosis and treatment
100. Letter on osteoporosis
101. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
102. Diphosphonates in the treatment of myositis ossificans
103. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans)
104. Clinical and biochemical effects of EHDP in Paget's disease of bone: Patterns of response to initial treatment and to long-term therapy
105. Effect of daily etidronate on the osteolysis of multiple myeloma
106. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma
107. Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group
108. Studies of the oral bioavailability of alendronate
109. New drugs for osteoporosis
110. Nutrient-drug interactions
111. The acute phase response after biphosphonate administration
112. Side-effects of pamidronate
113. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
114. Symptomatic hypocalcemia after treatment with high-dose aminohydroxypopylidene diphosphonate
115. Tolerability and safety of clodronate therapy in bone diseases
116. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
117. The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
118. Calcitonin: From the determination of circulating levels in various physiological and pathological conditions to the demonstration of lymphocyte receptors
119. Calcitonin: Physiology and pathophysiology
120. 25 Years of salmon calcitonin: From synthesis to therapeutic use
121. A double-blind placebo-controlled dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
122. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study
123. Clinical significance of antibodies against calcitonin
124. ACTH, cortisol and endorphin produced by calcitonin administration
125. Antalgic activity of calcitonin: Effectiveness of the epidural and sub-arachnoid routes in man
126. Calcitonins: Newer routes of delivery
127. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue
128. Effect of calcitonin on vertebral and other fractures
129. Evaluation and treatment of postmenopausal osteoporosis
130. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease
131. Neutralizing antibodies against calcitonin
132. Raloxifene for postmenopausal osteoporosis
133. Molecular basis of agonism and antagonism in the oestrogen receptor
134. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites
135. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
136. Therapy for fracture prevention
137. Effects of raloxifene (RLX), alendronate (ALN) and RLX+ ALN on bone mineral density (BMD) and biochemical markers on bone turnover in postmenopausal women with osteoporosis
138. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
139. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial
140. A controlled trial of raloxifene (LY 139481) HC1: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
141. What is the future for fluoride in the treatment of osteoporosis?
142. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride
143. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
144. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis
145. Fluoride treatment of osteoporosis: Cyclical non-blinded or continuous blinded studies?
146. Spinal fractures during fluoride therapy for osteoporosis: Relationship to spinal bone density
147. Fluoride: The verdict is in, but the controversy lingers
148. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy assessed by biomechanical testing of iliac cress biopsies in osteoporotic patients
149. 1,25 Dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells
150. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study
151. Fluoride therapy for osteoporosis: A review of dose response, duration of treatment, and skeletal sites of action
152. Treatment of osteoporosis with sodium fluoride: An appraisal
153. Mechanism of acute lower extremity pain syndrome in fluoride-treated osteoporotic patients
154. Skeletal scintigraphic changes in osteoporosis treated with sodium fluoride: Concise communication
155. Anabolic actions of parathyroid hormone on bone
156. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and estrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone
157. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial
158. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol
159. Randomised controlled study of effect of parathyroid hormone on vertebralbone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
160. Postmenopausal osteoporosis as a manifestation of renal hypercalciuria with secondary hyperparathyroidism
161. Thiazide diuretics and calcium metabolism
162. Thiazide for the postponement of postmenopausal bone loss
163. Thiazide effect on the mineral content of bone
164. Effects of thiazide diuretic therapy on bone mas, fractures, and falls
165. Thiazide diuretics and fractures: Can metaanalysis help?
166. Thiazide diuretic agents and the incidence of hip fracture
167. Long-term use of thiazide diuretics and risk of hip fracture